Immune system modulation via inserted human genes

"Immune system modulation via inserted human genes" is not a specific molecule, receptor, or canonical therapeutic target. Instead, it refers broadly to the strategy of using gene therapy techniques—such as inserting functional human genes into patient cells—to alter the immune system’s activity. This approach can involve delivering new genetic instructions using viral vectors (e.g., AAV, adenoviral, lentiviral) that may encode proteins modulating immune function or correcting genetic defects in immune-related pathways. The process faces significant challenges due to the body’s innate and adaptive immune responses against both the vector and any novel proteins produced; these can result in treatment failure or safety concerns such as inflammation and hypersensitivity reactions. Testing for pre-existing antibodies against delivery vehicles is often required before treatment. While this strategy underpins many modern therapies for inherited diseases and some cancers (e.g., CAR-T cell therapies), "immune system modulation via inserted human genes" is too broad and non-specific to be considered a single molecular target; rather, it describes an entire class of therapeutic approaches.[1][2][3][4]

Modulation of immune response by introducing or editing genes in immune cells or tissues[1][3][4]